Peripheral Cytokines and Chemokines in Alzheimer’s Disease

A chronic inflammatory process has been implicated in the neuropathology of Alzheimer’s disease (AD). The present review focuses on the current knowledge of circulating serum and plasma biomarkers of AD that are linked to inflammatory reactions. There is abundant evidence that inflammatory mechanisms within the central nervous system contribute to cognitive impairment via cytokine-mediated interactions between neurons and glial cells. Interleukins 1, 4, 6, 10, 12, 16, and 18, tumour necrosis factor, and several chemokines have been suggested as biomarkers of AD. Nonetheless, data on circulating cytokine levels are somewhat inconsistent with regard to peripheral cytokine dysregulation in AD. In summary, definite statements concerning differences in inflammatory biomarkers between controls and AD patients will require the use of sensitive multiplex assays in large patient groups in conjunction with measures of disease severity.

[1]  M. Tettamanti,et al.  Peripheral Inflammatory Response in Alzheimer's Disease and Multiinfarct Dementia , 2002, Neurobiology of Disease.

[2]  P. Peterson,et al.  Serum cytokine levels in patients with Alzheimer's disease. , 1994, Clinical and diagnostic laboratory immunology.

[3]  R. Kuljiš,et al.  The Role of Neuroimmunomodulation in Alzheimer's Disease , 2009, Annals of the New York Academy of Sciences.

[4]  C. Tinelli,et al.  Lymphocyte subset patterns and cytokine production in Alzheimer's disease patients , 2007, Neurobiology of Aging.

[5]  J. Lee,et al.  Changes in the levels of plasma soluble fractalkine in patients with mild cognitive impairment and Alzheimer's disease , 2008, Neuroscience Letters.

[6]  F. Stivala,et al.  Altered plasma cytokine levels in Alzheimer's disease: correlation with the disease progression. , 2007, Immunology letters.

[7]  R. Veerhuis,et al.  Costimulatory Effects of Interferon-γ and Interleukin-1β or Tumor Necrosis Factor α on the Synthesis of Aβ1-40 and Aβ1-42 by Human Astrocytes , 2000, Neurobiology of Disease.

[8]  V. Singh,et al.  Circulating cytokines in Alzheimer's disease. , 1997, Journal of psychiatric research.

[9]  Kaj Blennow,et al.  Cerebrospinal fluid protein biomarkers for Alzheimer’s disease , 2004, NeuroRX.

[10]  M. O’Banion,et al.  The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective , 2008, Journal of Neuroinflammation.

[11]  B. Pedersen,et al.  A high plasma concentration of TNF-alpha is associated with dementia in centenarians. , 1999, The journals of gerontology. Series A, Biological sciences and medical sciences.

[12]  Peter Riederer,et al.  Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients , 1995, Neuroscience Letters.

[13]  H. Hinterhuber,et al.  Measurement of Thirteen Biological Markers in CSF of Patients with Alzheimer’s Disease and Other Dementias , 2005, Dementia and Geriatric Cognitive Disorders.

[14]  R. Veerhuis,et al.  Costimulatory effects of interferon-gamma and interleukin-1beta or tumor necrosis factor alpha on the synthesis of Abeta1-40 and Abeta1-42 by human astrocytes. , 2000, Neurobiology of disease.

[15]  C. Paladini,et al.  Alzheimer Patients Treated With an AchE Inhibitor Show Higher IL-4 and Lower IL-1β Levels and Expression in Peripheral Blood Mononuclear Cells , 2004, Journal of clinical psychopharmacology.

[16]  H. Wiśniewski,et al.  α1-Antichymotrypsin and IL-1β are not increased in CSF or serum in Alzheimer's disease , 1994, Neurobiology of Aging.

[17]  E. Porreca,et al.  Proinflammatory cytokines in sera of elderly patients with dementia: levels in vascular injury are higher than those of mild–moderate Alzheimer's disease patients , 2002, Experimental Gerontology.

[18]  K. Blennow,et al.  Inflammatory Markers in Matched Plasma and Cerebrospinal Fluid from Patients with Alzheimer’s Disease , 2003, Dementia and Geriatric Cognitive Disorders.

[19]  R. Tibshirani,et al.  Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins , 2007, Nature Medicine.

[20]  E. Bosmans,et al.  Serotonin-immune interactions in elderly volunteers and in patients with Alzheimer’s disease (DAT): Lower plasma tryptophan availability to the brain in the elderly and increased serum interleukin-6 in DAT , 1998, Aging.

[21]  K. Blennow,et al.  Intracerebral Production of Tumor Necrosis Factor-α, a Local Neuroprotective Agent, in Alzheimer Disease and Vascular Dementia , 1999, Journal of Clinical Immunology.

[22]  L. Fernández-Novoa,et al.  Blood levels of histamine, IL-1β, and TNF-α in patients with mild to moderate alzheimer disease , 1996 .

[23]  N. Christophidis,et al.  Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer's disease , 1998, Neuroscience Letters.

[24]  R. D'Hooge,et al.  Unchanged levels of interleukins, neopterin, interferon-γ and tumor necrosis factor-α in cerebrospinal fluid of patients with dementia of the Alzheimer type , 1999, Neurochemistry International.

[25]  L. Fernández-Novoa,et al.  Serum tumor necrosis factor (TNF) in Alzheimer's disease and multi-infarct dementia. , 1994, Methods and findings in experimental and clinical pharmacology.

[26]  H. Möller,et al.  Decreased soluble interleukin-6 receptor in cerebrospinal fluid of patients with Alzheimer's disease , 1998, Brain Research.

[27]  M. Barquero,et al.  Cerebrospinal fluid interleukin-1 beta (IL-1 beta) in Alzheimer's disease and neurological disorders. , 1991, Methods and findings in experimental and clinical pharmacology.

[28]  M. Barcikowska,et al.  Plasma beta amyloid and cytokine profile in women with Alzheimer's disease. , 2008, Neuro endocrinology letters.

[29]  P. Scheltens,et al.  Chemokines in serum and cerebrospinal fluid of Alzheimer's disease patients , 2003, Annals of neurology.

[30]  A. M. Szczepanik,et al.  IL-4, IL-10 and IL-13 modulate Aβ(1–42)-induced cytokine and chemokine production in primary murine microglia and a human monocyte cell line , 2001, Journal of Neuroimmunology.

[31]  R. Dantzer,et al.  Interleukin-10 in the brain. , 2001, Critical reviews in immunology.

[32]  K. Blennow,et al.  Local and systemic GM‐CSF increase in Alzheimer's disease and vascular dementia , 2001, Acta neurologica Scandinavica.

[33]  R J Fulton,et al.  Advanced multiplexed analysis with the FlowMetrix system. , 1997, Clinical chemistry.

[34]  L. Fernández-Novoa,et al.  Blood levels of histamine, IL-1 beta, and TNF-alpha in patients with mild to moderate Alzheimer disease. , 1996, Molecular and chemical neuropathology.

[35]  Stavros J. Baloyannis,et al.  Systemic immune aberrations in Alzheimer's disease patients , 2008, Journal of Neuroimmunology.

[36]  B. Bergamasco,et al.  Increased intrathecal TGF-beta1, but not IL-12, IFN-gamma and IL-10 levels in Alzheimer's disease patients. , 2006, Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology.

[37]  R. Maccioni,et al.  Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. , 2008, Archives of medical research.

[38]  Min-Jeong Shin,et al.  Bioplex analysis of plasma cytokines in Alzheimer's disease and mild cognitive impairment. , 2008, Immunology letters.

[39]  A. Smith,et al.  Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin. , 1998, Alzheimer disease and associated disorders.

[40]  A. Suzumura,et al.  Increased Soluble Tumor Necrosis Factor Receptor Levels in the Serum of Elderly People , 2000, Gerontology.

[41]  B. Bergamasco,et al.  Increased intrathecal TGF-β1, but not IL-12, IFN-γ and IL-10 levels in Alzheimer’s disease patients , 2006, Neurological Sciences.

[42]  Z. Janka,et al.  Serum interleukin‐6 levels correlate with the severity of dementia in Down syndrome and in Alzheimer's disease , 1997, Acta neurologica Scandinavica.

[43]  L. Buée,et al.  Elevated circulating tumor necrosis factor levels in Alzheimer's disease , 1991, Neuroscience Letters.

[44]  P. Gil,et al.  Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease. , 2008, Immunology letters.

[45]  V. Costa,et al.  Cytokines in Alzheimer's Disease and Vascular Dementia , 2008, The International journal of neuroscience.

[46]  H. Wiśniewski,et al.  Alpha 1-antichymotrypsin and IL-1 beta are not increased in CSF or serum in Alzheimer's disease. , 1994, Neurobiology of aging.

[47]  R. D'Hooge,et al.  Unchanged levels of interleukins, neopterin, interferon-gamma and tumor necrosis factor-alpha in cerebrospinal fluid of patients with dementia of the Alzheimer type. , 1999, Neurochemistry international.

[48]  G. Annoni,et al.  Increased plasma levels of interleukin-1, interleukin-6 and α-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? , 2000, Journal of Neuroimmunology.

[49]  D. Gambi,et al.  IL-4 in vitro production is upregulated in Alzheimer's disease patients treated with acetylcholinesterase inhibitors , 2004, Experimental Gerontology.

[50]  J. Vente,et al.  Biochemical markers related to Alzheimer’s dementia in serum and cerebrospinal fluid , 2002, Neurobiology of Aging.

[51]  Gilbert J Ho,et al.  Interleukins, inflammation, and mechanisms of Alzheimer's disease. , 2006, Vitamins and hormones.

[52]  M. Herkenham,et al.  Connecting cytokines and brain: a review of current issues. , 2002, Histology and histopathology.

[53]  E. Bosmans,et al.  Inflammatory markers in younger vs elderly normal volunteers and in patients with Alzheimer's disease. , 1999, Journal of psychiatric research.

[54]  P. Eikelenboom,et al.  Neuroinflammatory perspectives on the two faces of Alzheimer’s disease , 2004, Journal of Neural Transmission.

[55]  R. Rydel,et al.  Amyloid beta peptide potentiates cytokine secretion by interleukin-1 beta-activated human astrocytoma cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.